ARTICLE
TITLE

Pharmacokinetic profile of iron serum after ingestion of ferrous sulfate tablet 2 300 mg taken shortly after meal and 2 hours after meal in women with iron deficiency anaemia

SUMMARY

Background: Iron supplementation is a common strategy used to control iron deficiency anaemia in developing countries. Despite of that, the prevalence of anaemia is still high. Several factors causing the failure of iron supplementation program were reported. The increase in haemoglobin concentration after iron supplementation was determined by several factors, that is, the dose, iron absorption, body iron store, diet, food, and pregnancy. There had been studies on iron pharmacokinetic profile after ingestion of iron tablet taken shortly after meal compared to 2 hours after meal in healthy women, but there was no study on women with iron deficiency anaemia.Aim: The aim of this study was to find out the effect of ferrous suphate @ 300 mg taken shortly after meal and 2 hours after meal on the iron pharmacokinetic profile in women with iron deficiency anaemia.Materials and method: This study was conducted with cross-over design, so that every subject had 2 interventions with an interval (washed-out period) of 7 days. In intervention 1, ferrous sulfate tablet @ 300 mg was taken shortly after meal, and in intervention 2, the tablet was taken 2 hours after meal. Serum samples were taken serially at 0, 0.25, 0.5, 1, 1.5. 2, 2.5, 3, 4, 6, 8, 10 and 12 hours after taking iron tablets. Ferric iron concentration in serum was determined by Vitros Fe Slides method, and iron pharmacokinetic profile was determined using non-compartmental method.Result: The values of pharmacokinetic parameter from the first and second interventions were compared by t test, and the result (mean:t SEMI were: Cmox 274.25 :t 28.18 and 232.92 :t 33.25 ug/dl, T mox 3.21:t 0.30 and 4.25 :t 0.64 hours, K.0.437 :t 0.0011 and 0.3808 :t 0.0065 hour'" Kel 0.1375 :t 0.0132 and 0.1855 :t 0.0048 hour". T'/2e' 5.76 :t 0.74 and 5.81 :t 1.16 hours and AUCO-,2 2157.37 :t 264.55 and 1869.54 :t 330.60 ug/dl.hours. There are no significant differences in all pharmacokinetic parameters between both interventions.Conclusion: There are no differences in iron pharmacokinetic profiles after ferrous sulfate tablet @ 300 mg taken after meal and 2 hours after meal in women with iron deficiency anaemiaKata kunci:iron concentration, pharmacokinetics, ferrous sulfate, anemia, effect of food

 Articles related

Purnama Fajri, Ari Estuningtyas, Melva Louisa, Hans-Joachim Freisleben    

Background: Recently, there is no agent available for the prevention of iron overload (IO) in thalassemia patients. Previous studies showed that Mangifera foetida L. leaf extracts reduced the levels of iron in IO in vitro and in vivo models. The present ... see more


Dedy Afandi, Sri Mulatsih, Madarina Julia    

Background: Complianc~ of daily treatment of iron deficiency anemia in children is still low. The compliance will be increased if the iron supplementation is given weekly. Previous study showed that there was no significant difference in the increase in ... see more


Tonny Sadjimin Tonny Sadjimin    

The objective of the study was to examine the effectiveness of iron-fortification milk as a supplementation feeding for pregnant women in preventing the incidence of low birth weight. The design of the study was randomized controlled double-masked commun... see more


K. Schümann,N. W. Solomons,M. Orozco,M. E. Romero-Abal,G. Weiss    

Background. The adverse interactions between iron supplements and malaria have driven the assessment of new therapeutic options for anemia prophylaxis in areas holoendemic for falciparum malaria.Objective. To determine the responses of circulating non-tr... see more


Uso de la spirulina en gestante con betatalasemia menor heterocigótica. A propósito de un caso Uso de la spirulina en gestante con betatalasemia menor heterocigótica. A propósito de un casoIntroducción: la hemoglobina es una proteína tetramérica responsable del transporte de oxígeno a las células y tejidos del cuerpo, formada por cuatro subunidades: dos subunidades a-globina y dos subunidades ß-globina (a2, ß2), la mayoría de individuos heterocigotos (ß+/ß ó ßo/ß) son portadores silenciosos que no manifiestan síntomas (ß-talasemia menor); a veces, pueden presentar episodios leves de anemia. Objetivo: presentar un caso de gestante con betatalasemia menor heterocigótica, destacando la eficacia del suplemento Spirel.Presentación del caso: gestanteresidente en Provincia Mayabeque, con antecedentes de betatalasemia menor heterocigota con tratamiento de ácido fólico; en embarazo anterior recibió 13 transfusiones manteniendo hemoglobina de 3 a 4 g/l), a las 23,5 semanas. Una vez recibida la primera terapia transfusional se aplican 3 tabletas 30 minutos después de desayuno, almuerzo y comida del suplemento Spirel que contiene Spirulina Platensis (Sp),  proteínas, vitaminas, y otros compuestos con 16 g de hierro broquelado. Conclusiones: la evolución de este caso destaca la eficacia del suplemento Spirel en el incremento de la hemoglobina, peso materno, altura uterina y el peso del neonato en las gestantes con betatalasemia.Palabras clave: hemoglobinopatía, cetatalasemia, hierro bioquelado, spirel, spirulina, gestante.ABSTRACTIntroduction: The hemoglobin is a protein tetrameric carrier of oxygen to the cells and tissues of the body, composed by four subunits: two a-Globin sub units and two of ß-Globin (a-2, ß-2), most  of individuals heterozygote  ß+/ß or ßo/ß) They are silent carries that do not manifest symptoms (ß thalassemia minor) sometimes, can present mild anemia episode. Objective: Present a case of pregnant with heterozygoteß thalassemia minor enhancing the efficiency of the supplement Spirel. Case presentation: A Pregnant woman resident in Mayabeque Province, with antecedents of heterozygote ß thalassemia minor with treatment of folic acid , in a previous pregnancy received 13 transfusions keeping hemoglobin of 3 to 4 g/l). To the 23,5 weeks. Once received the first therapy transfusion are given 3 pills 30 minutes after breakfast, lunch  and dinner of Spirel containing Spirulin Platensis (Sp), proteins, vitamins, and other compounds with 16 g of chelate iron. Conclusions: The presentation of this case remarks the efficacy of the Spirel supplement according to hemoglobin, maternal weight, uterine height, and the newborn weight, in pregnant with a diagnosis of ß thalassemia minor.Keywords: hemoglobinopaty, betatalasemia. iron bioquelado, spirel, spiruline, pregnant.

Mayra Visia Quiñones Martínez,Rolando Campo Rodríguez,Laura Elena Gil Rojas    

Objetivo: presentar un caso de gestante con betatalasemia menor heterocigótica, destacando la eficacia del suplemento Spirel.Presentación del caso: gestanteresidente en Provincia Mayabeque, con antecedentes de betatalasemia menor heterocigota con tratami... see more